LEADER 02276nam 2200337 450 001 9910688341003321 005 20230623055341.0 035 $a(CKB)3710000001092170 035 $a(NjHacI)993710000001092170 035 $a(EXLCZ)993710000001092170 100 $a20230623d2017 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRecent Advances in HTLV Research 2015 /$fLouis M. Mansky 210 1$a[Place of publication not identified] :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2017. 215 $a1 online resource (352 pages) 311 $a3-03842-377-7 330 $aThe human T-cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-2) were both discovered over three decades ago and infect millions people worldwide. HTLV-1 is associated with the adult T-cell leukemia/lymphoma (ATLL) in about 2% of individuals infected, and another 2 to 3% of individuals develop a neurologic disorder called HTLV-associated myelopathy (HAM). HTLV-2 causes HAM in approximately 1 to 2% of infected individuals, but does not cause ATLL. HTLV-1 and HTLV-2 have served as excellent models for the study of the epidemiology and pathogenesis of virus-associated cancers as well as autoimmune conditions such as multiple sclerosis. Recently, two new members--HTLV-3 and HTLV-4--have been discovered in bushmeat hunters from central Africa, which emphasizes the urgent need for continual surveillance for new human retroviruses and their capacity to cause disease. Important public health issues remain open issues to be addressed in spite of the basic epidemiology of HTLV-1 and HTLV-2 being reasonably well defined. Clinical research is needed in developing potential HTLV-1 and HTLV-2 vaccines, as well as development of treatment options for ATLL and HAM. This 'Recent Advances Issue' contains both reviews and updates on research that encompasses these areas. 606 $aHTLV (Viruses) 615 0$aHTLV (Viruses) 676 $a616.994071 700 $aMansky$b Louis M.$01367411 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910688341003321 996 $aRecent Advances in HTLV Research 2015$93390473 997 $aUNINA